UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  February 13, 2007

 

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-31191

 

04-3324394

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

                      

8 Campus Drive

 

 

Parsippany, New Jersey

 

07054

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (973) 656-1616

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



Item 5.02.  Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 13, 2007, the Compensation Committee of the Board of Directors of The Medicines Company established the following 2007 base salaries for the Company’s executive officers, effective as of January 1, 2007, and awarded the following annual cash bonus payments to the Company’s executive officers for 2006.

 

 

2007 Annual Base Salary

 

2006 Annual Cash Bonus
Payments

 

Clive A. Meanwell
Chief Executive Officer

 

$

566,000

 

$

387,000

 

John P. Kelley
President and Chief
Operating Officer

 

$

450,000

 

$

250,000

 

Glenn P. Sblendorio
Executive Vice President
and Chief Financial Officer

 

$

375,000

 

$

165,000

 

Catharine Newberry
Senior Vice President and
Chief Human Strategy Officer

 

$

285,000

 

$

109,000

 

Paul M. Antinori
Senior Vice President and
General Counsel

 

$

315,000

 

$

139,200

 

 

2



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE MEDICINES COMPANY

 

 

 

 

 

 

 

 

 

 

Date: February 16, 2007

 

By:

 

/s/ Paul M. Antinori

 

 

 

 

Paul M. Antinori

 

 

 

 

Senior Vice President and General Counsel

 

3